Smith & Nephew SNATS (SNN)
(Delayed Data from NYSE)
$28.52 USD
+0.17 (0.60%)
Updated Jul 23, 2024 04:00 PM ET
2-Buy of 5 2
A Value B Growth D Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SNN 28.52 +0.17(0.60%)
Will SNN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SNN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SNN
Smith & Nephew's (SNN) CATALYSTEM System Gets FDA Clearance
Smith & Nephew's (SNN) 5% Stake Acquired by Cevian Capital
SNN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Smith & Nephew's (SNN) CORIOGRAPH to Aid Arthroplasty Procedure
Smith+Nephew (SNN) Expands in Australia With New Alliance
Fresenius Medical (FMS) to Unveil Training on Augmented Reality
Other News for SNN
LONDON BROKER RATINGS: Deutsche Bank starts Smith & Nephew at 'buy'
LONDON BRIEFING: Reckitt to simplify; Informa agrees Ascential buy
Best-in-class just got better; Smith+Nephew announces 510(k) clearance of new CATALYSTEMâ„¢ Primary Hip System
Smith & Nephew announces 510(k) clearance for CATALYSTEM Primary Hip System
Smith+Nephew is trailblazing a new path for female surgeons with its Orthopaedics for All initiative; a first-of-its-kind global advisory board